Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia
Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia
复制标题
DOI：
10.1016/j.psychres.2016.08.055
复制
发表时间：
2016-11-30
影响因子：
11.3
通讯作者：
Sharma, Rajiv P.
中科院分区：
文献类型：
--
作者：
Chase, Kayla A.;Feiner, Benjamin;Sharma, Rajiv P.
大麻素受体信号与精神病易感性之间的关系需要进一步探讨。内源性大麻素信号系统广泛，受体在免疫和中枢神经系统中发挥调节功能。在大脑中，大麻素受体(CBR)直接调节神经递质系统。在外周淋巴细胞中，CBRS介导细胞因子的释放，在精神分裂症中表现出细胞因子水平的异常。检测了70例因不吸食/滥用大麻而自行招募的受试者(非临床对照组35例，精神分裂症患者35例)外周血单个核细胞(PBMCs)中CBRs的mRNA水平。采用定量逆转录-聚合酶链式反应(qRT-PCR)检测基因表达的变化。临床测量包括Matrics认知成套测验和阳性与阴性症状量表。精神分裂症患者PBMCs中CB1R和CB2R基因表达水平显著高于非临床对照组。此外，CB1R和CB2R的mRNA水平与多个领域的认知加工障碍和临床症状严重程度相关。这些结果继续支持精神分裂症患者中内源性大麻素信号系统特定方面的失调，这些患者被选为自我报告没有滥用/依赖大麻的患者。爱思唯尔爱尔兰有限公司出版。
The relationship between cannabinoid receptor signaling and psychosis vulnerability requires further exploration. The endocannabinoid signaling system is extensive, with receptors exerting regulatory functions in both immune and central nervous systems. In the brain, cannabinoid receptors (CBR) directly modulate neurotransmitter systems. In the peripheral lymphocyte, CBRs mediate cytokine release, with dysregulated cytokine levels demonstrated in schizophrenia. mRNA levels of CBRs were measured in human peripheral blood mononuclear cells (PBMCs) obtained from 70 participants (35 non-clinical controls, 35 participants with schizophrenia), who were recruited for the absence of marijuana use/abuse by self-report. Changes in mRNA expression were measured using qRT-PCR. Clinical measurements collected included the MATRICS Cognitive Battery and the Positive and Negative Syndrome Scale. Levels of CB1R and CB2R mRNA in PBMCs were significantly higher in participants with schizophrenia compared to the non-clinical controls. Additionally, CB1R and CB2R mRNA levels correlated with impairments in cognitive processing and clinical symptom severity in multiple domains. These results continue to support dysregulation of particular aspects of the endocannabinoid signaling system in participants with schizophrenia selected for the self-reported absence of marijuana abuse/dependence. Published by Elsevier Ireland Ltd.